Skip to main content
GutCited

Lactobacillus gasseri per Helicobacter pylori Infection

B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

Key Study Findings

In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None vs: H. pylori infection without lactobacilli Outcome: ADAM17, HBEGF, TGF-alpha expression Effetto: None None

Popolazione: AGS gastric epithelial cells and mouse model

In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None vs: CagA-expressing AGS cells without L. gasseri Outcome: Suppression of CagA phosphorylation (hummingbird) Effetto: None None

Popolazione: Human gastric AGS cell line with H. pylori CagA

In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml vs: None Outcome: Inflammatory markers Effetto: None None

Popolazione: None

Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None vs: None Outcome: Inflammatory markers Effetto: None None

Popolazione: Cancer patients

Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None vs: None Outcome: H. pylori abundance reduction Effetto: None None

Popolazione: H. pylori-infected C57BL/6 mice

Case-Control n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None vs: None Outcome: Oral/gastric microbiome associations with IM Effetto: None None

Popolazione: Gastric intestinal metaplasia cases and matched controls

Key Statistics

3

Studi

350

Partecipanti

↑

Positive

B

Grado

Referenced Papers

International journal of … 2022 59 citazioni
Comparative immunology, microbiology … 2019 72 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1-10 billion CFU/day
gerdsupport:
1-5 billion CFU/day
hpylorisupport:
100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks

Limite massimo: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
None -- Positive --
50 μg/ml -- Mixed --
None -- Positive --
None -- Positive --
None -- Neutral 178
None -- Positive --
1 g -- Positive --

Momento migliore per l'assunzione: Before meals or with meals; yogurt form taken with food

Safety & Side Effects

Effetti collaterali segnalati

  • ⚠ Mild gas during initial use
  • ⚠ Occasional loose stools
  • ⚠ Rare abdominal discomfort
  • ⚠ Very rare: bacteremia in immunocompromised individuals

Interazioni note

  • ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • ● Proton pump inhibitors (altered gastric pH may affect colonization)
  • ● Immunosuppressants (theoretical risk in immunocompromised patients)

Livello di assunzione massimo tollerabile: Well-tolerated up to 10 billion CFU/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Lactobacillus gasseri help with Helicobacter pylori Infection?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus gasseri may support Helicobacter pylori Infection management. Our evidence grade is B (Good Evidence).
How much Lactobacillus gasseri should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Helicobacter pylori Infection?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.

Altri ingredienti per Helicobacter pylori Infection

Lactobacillus gasseri per altre condizioni

References

  1. [1] Rajesh K Gupta et al.. Int J Mol Sci. 2025. Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction. doi:10.3390/ijms26146718 PubMed
  2. [2] Tanvi Somiah et al.. Int J Med Microbiol. 2025. Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in gastric host cells. doi:10.1016/j.ijmm.2025.151694 PubMed
  3. [3] Zahra Sadeghloo et al.. Microb Pathog. 2024. The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of Helicobacter pylori in gastric epithelial … doi:10.1016/j.micpath.2024.106559 PubMed
  4. [4] Marine Jauvain et al.. Helicobacter. 2024. Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection. doi:10.1111/hel.13108 PubMed
  5. [5] Fen Wu et al.. Int J Cancer. 2022. Oral and gastric microbiome in relation to gastric intestinal metaplasia. doi:10.1002/ijc.33848 PubMed
  6. [6] Tran Thi Dieu Thuy et al.. BMC Microbiol. 2022. Anti-Helicobacter pylori activity of potential probiotic Lactiplantibacillus pentosus SLC13. doi:10.1186/s12866-022-02701-z PubMed
  7. [7] Yuyang Zhao et al.. Food Funct. 2022. Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori infection in C57BL/6 mice. doi:10.1039/d2fo02034c PubMed
  8. [8] Mahdieh Yarmohammadi et al.. Probiotics Antimicrob Proteins. 2021. Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected … doi:10.1007/s12602-020-09721-z PubMed
  9. [9] Majid Eslami et al.. Comp Immunol Microbiol Infect Dis. 2019. Are probiotics useful for therapy of Helicobacter pylori diseases? doi:10.1016/j.cimid.2019.02.010 PubMed
  10. [10] Hanna G Gebremariam et al.. Front Immunol. 2019. Lactobacillus gasseri Suppresses the Production of Proinflammatory Cytokines in Helicobacter pylori-Infected Macrophages by Inhibiting the Expression of ADAM17. doi:10.3389/fimmu.2019.02326 PubMed
  11. [11] Fanglei Zuo et al.. Front Microbiol. 2019. Role of Sortase A in Lactobacillus gasseri Kx110A1 Adhesion to Gastric Epithelial Cells and Competitive Exclusion of Helicobacter pylori. doi:10.3389/fmicb.2019.02770 PubMed
  12. [12] Yasuhiro Koga et al.. BMJ Open Gastroenterol. 2019. Probiotic L. gasseri strain (LG21) for the upper gastrointestinal tract acting through improvement of indigenous microbiota. doi:10.1136/bmjgast-2019-000314 PubMed
  13. [13] Toshihiro Ohtsu et al.. Digestion. 2017. The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study. doi:10.1159/000479000 PubMed
  14. [14] Atsushi Takagi et al.. Gastroenterol Res Pract. 2016. Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. doi:10.1155/2016/7490452 PubMed
  15. [15] Hidenori Matsui et al.. Helicobacter. 2015. Mouse Models for Assessing the Protective Efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis Infection Associated with the Development of … doi:10.1111/hel.12203 PubMed
  16. [16] Yini Dang et al.. PLoS One. 2014. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. doi:10.1371/journal.pone.0111030 PubMed
  17. [17] Susana Delgado et al.. Front Microbiol. 2014. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric … doi:10.3389/fmicb.2014.00766 PubMed
  18. [18] Kurt Selle et al.. FEMS Microbiol Rev. 2013. Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health. doi:10.1111/1574-6976.12021 PubMed
  19. [19] Ryuzo Deguchi et al.. J Gastroenterol Hepatol. 2012. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. doi:10.1111/j.1440-1746.2011.06985.x PubMed
  20. [20] Xiaohua Chen et al.. J Food Sci. 2012. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. doi:10.1111/j.1750-3841.2011.02498.x PubMed
  21. [21] Shigeru Fujimura et al.. J Clin Microbiol. 2012. Probiotic mechanism of Lactobacillus gasseri OLL2716 strain against Helicobacter pylori. doi:10.1128/JCM.06262-11 PubMed
  22. [22] X Chen et al.. J Dairy Sci. 2010. In vitro screening of lactobacilli with antagonistic activity against Helicobacter pylori from traditionally fermented foods. doi:10.3168/jds.2010-3449 PubMed
  23. [23] Yuko Kato-Mori et al.. J Med Food. 2010. Fermentation metabolites from Lactobacillus gasseri and Propionibacterium freudenreichii exert bacteriocidal effects in mice. doi:10.1089/jmf.2010.1137 PubMed
  24. [24] Luc De Vuyst et al.. Probiotics Antimicrob Proteins. 2010. Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. doi:10.1007/s12602-009-9029-4 PubMed
  25. [25] Surasak Boonyaritichaikij et al.. Helicobacter. 2009. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. doi:10.1111/j.1523-5378.2009.00675.x PubMed
  26. [26] Takeshi Shimosato et al.. Cell Microbiol. 2006. Strong immunostimulatory activity of AT-oligodeoxynucleotide requires a six-base loop with a self-stabilized 5'-C...G-3' stem structure. doi:10.1111/j.1462-5822.2005.00640.x PubMed
  27. [27] Akira Tamura et al.. J Gastroenterol Hepatol. 2006. Suppression of Helicobacter pylori-induced interleukin-8 production in vitro and within the gastric mucosa by a live Lactobacillus strain. doi:10.1111/j.1440-1746.2006.04318.x PubMed
  28. [28] S Fujimura et al.. Lett Appl Microbiol. 2006. Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. doi:10.1111/j.1472-765X.2006.02017.x PubMed
  29. [29] Masayuki Uchida et al.. J Pharmacol Sci. 2004. Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against [correction of agaisnt] acute gastric lesion and antral ulcer in rats. doi:10.1254/jphs.fpj04027x PubMed
  30. [30] Atsushi Ushiyama et al.. J Gastroenterol Hepatol. 2003. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. doi:10.1046/j.1440-1746.2003.03102.x PubMed
  31. [31] Toshiaki Shimizu et al.. J Antimicrob Chemother. 2002. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. doi:10.1093/jac/dkf157 PubMed
  32. [32] I Sakamoto et al.. J Antimicrob Chemother. 2001. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. doi:10.1093/jac/47.5.709 PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.